UBC

UBC is onsite at #ESMO2025, joining global leaders in oncology to advance cancer care across the therapeutic lifecycle. Our teams are available to discuss how our consultative approach and deep expertise in evidence generation, safety, and risk management can support your oncology programs from development through commercialization. Let’s connect: https://hubs.li/Q03NzqX50 Al Blunt, Rosanna Duffy, Frederique Lahache

We're in Boston, ready to delve into the ins and outs of clinical and outsourcing operations! Schedule a time to meet with our evidence development and safety and risk management teams and learn how our modern, customized solutions can benefit your clinical trials: https://hubs.li/Q03MG4Z70 #PatientsFirst #ClinicalTrials #UBC

UBC is proud to attend the NORD Breakthrough Summit, where leaders in orphan product development come together to share insights and advance innovation in rare disease research. Our team looks forward to connecting with industry colleagues and exploring new ways to design clinical trials that are both effective and patient-centered. https://hubs.li/Q03Nwfz70 #PatientsFirst #UBC

Our own Aaron Berger had a chance to sit down and talk with Joel White a bit ago, and we're excited to share the outcome of that conversation with you. Joel has long been an important voice in the life sciences space, always with his finger on the pulse of our industry, and we look forward to hearing your thoughts on this chat for Evidence Matters. Link: https://lnkd.in/eSUQCEci

We’re looking forward to joining global leaders in oncology at #ESMO2025. If advancing cancer care through real-world evidence or strengthening safety and risk management strategies is part of your focus, we’d welcome the opportunity to connect. Our team brings deep therapeutic expertise and a commitment to patient-first innovation. Plan a meeting with us during the congress: https://hubs.li/Q03N57180 Frederique Lahache Al Blunt Rosanna Duffy #PatientsFirst #RiskManagement #EvidenceDevelopment

In a recent interview, Aaron Berger, SVP & Head of Evidence Development Solutions at UBC, discusses the operational and scientific impact of direct-to-patient study designs. He shares how UBC is helping sponsors navigate the shift toward more accessible, flexible, and patient-centric research models. Read the full blog post to explore how decentralization is driving innovation in clinical trial design and real-world evidence generation: https://hubs.li/Q03MQp-y0 #PatientsFirst #EvidenceDevelopment #RealWorldEvidence #UBC

Good data management early in the pharmacovigilance process protects developers against regulatory noncompliance and ultimately protects patients against exposure to undue risks associated with a medicinal product. Experts share how advances in data management systems and technologies can ensure every safety signal is accurately detected and reported on time: https://hubs.li/Q03MG9xD0 #Pharmacovigilance #PatientSafety #PublicHealth #PVData #SafetySignals #PatientsFirst

Will you be attending Outsourcing in Clinical Trials New England next week? If you're exploring real-world evidence strategies designed for specialty populations, or seeking proven approaches to safety and risk management, our team at UBC is ready to connect. We bring deep expertise and a commitment to advancing patient-centric solutions in clinical development. Let’s talk—schedule a meeting: https://hubs.li/Q03MG6w30 #PatientsFirst #ClinicalTrials

In this episode of tHEORetically Speaking, Aaron Berger SVP & Head of Evidence Development Solutions at UBC, dives into how direct-to-patient (DTP) study designs are reshaping the way we think about trial accessibility, engagement, and data quality.   From operational efficiencies to improved patient outcomes, decentralization is unlocking new possibilities.   Listen to the full interview here: https://lnkd.in/ehddZy7W

We're excited to be at #WorldDrugSafety Congress Europe! We'd love to chat with you about QPPV risk oversight and audit-resilient delegation models. And don't miss UBC's Peter Psarologos, speaking today about how to stay inspection-ready and compliant under EU Regulation 2025/1466. https://hubs.li/Q03Mv88C0 #PatientsFirst #Pharmacovigilance #WDSC2025